279 related articles for article (PubMed ID: 23564602)
1. Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition.
Ulloa JL; Stahl S; Yates J; Woodhouse N; Kenna JG; Jones HB; Waterton JC; Hockings PD
NMR Biomed; 2013 Oct; 26(10):1258-70. PubMed ID: 23564602
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.
Scotcher D; Melillo N; Tadimalla S; Darwich AS; Ziemian S; Ogungbenro K; Schütz G; Sourbron S; Galetin A
Mol Pharm; 2021 Aug; 18(8):2997-3009. PubMed ID: 34283621
[TBL] [Abstract][Full Text] [Related]
3. Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis.
Giraudeau C; Leporq B; Doblas S; Lagadec M; Pastor CM; Daire JL; Van Beers BE
Eur Radiol; 2017 May; 27(5):1804-1811. PubMed ID: 27553933
[TBL] [Abstract][Full Text] [Related]
4. A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.
Karageorgis A; Lenhard SC; Yerby B; Forsgren MF; Liachenko S; Johansson E; Pilling MA; Peterson RA; Yang X; Williams DP; Ungersma SE; Morgan RE; Brouwer KLR; Jucker BM; Hockings PD
PLoS One; 2018; 13(5):e0197213. PubMed ID: 29771932
[TBL] [Abstract][Full Text] [Related]
5. Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver.
Lagadec M; Doblas S; Giraudeau C; Ronot M; Lambert SA; Fasseu M; Paradis V; Moreau R; Pastor CM; Vilgrain V; Daire JL; Van Beers BE
Radiology; 2015 Feb; 274(2):379-86. PubMed ID: 25289480
[TBL] [Abstract][Full Text] [Related]
6. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
Li X; Zhong K; Guo Z; Zhong D; Chen X
Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
[TBL] [Abstract][Full Text] [Related]
7. Hepatic Phospholipidosis Is Associated with Altered Hepatobiliary Function as Assessed by Gadoxetate Dynamic Contrast-enhanced Magnetic Resonance Imaging.
Lenhard SC; Lev M; Webster LO; Peterson RA; Goulbourne CN; Miller RT; Jucker BM
Toxicol Pathol; 2016 Jan; 44(1):51-60. PubMed ID: 26516164
[TBL] [Abstract][Full Text] [Related]
8. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B; Xu JJ; Bi YA; Mireles R; Davidson R; Duignan DB; Campbell S; Kostrubsky VE; Dunn MC; Smith AR; Wang HF
Toxicol Sci; 2009 Apr; 108(2):492-500. PubMed ID: 19223659
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.
Barber JA; Stahl SH; Summers C; Barrett G; Park BK; Foster JR; Kenna JG
Toxicol Sci; 2015 Nov; 148(1):48-59. PubMed ID: 26220638
[TBL] [Abstract][Full Text] [Related]
10. Optimized Hepatocyte-Like Cells with Functional Drug Transporters Directly-Reprogrammed from Mouse Fibroblasts and their Potential in Drug Disposition and Toxicology.
Wu ZT; Yao D; Ji SY; Ni X; Gao YM; Hui LJ; Pan GY
Cell Physiol Biochem; 2016; 38(5):1815-30. PubMed ID: 27160211
[TBL] [Abstract][Full Text] [Related]
11. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte Concentrations of Imaging Compounds Associated with Transporter Inhibition: Evidence in Perfused Rat Livers.
Bonnaventure P; Cusin F; Pastor CM
Drug Metab Dispos; 2019 Apr; 47(4):412-418. PubMed ID: 30674615
[TBL] [Abstract][Full Text] [Related]
13. [Transporters involved in hepatobiliary transport of drugs].
Maeda K
Nihon Yakurigaku Zasshi; 2010 Feb; 135(2):76-9. PubMed ID: 20154415
[No Abstract] [Full Text] [Related]
14. Dynamic contrast-enhanced MRI of the liver in Mrp2-deficient rats using the hepatobiliary contrast agent Gd-EOB-DTPA.
Saito S; Obata A; Kashiwagi Y; Abe K; Murase K
Invest Radiol; 2013 Jul; 48(7):548-53. PubMed ID: 23442774
[TBL] [Abstract][Full Text] [Related]
15. The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism.
Sheng J; Tian X; Xu G; Wu Z; Chen C; Wang L; Pan L; Huang C; Pan G
Drug Metab Dispos; 2015 Jan; 43(1):63-72. PubMed ID: 25336752
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.
Jiang R; Dong J; Li X; Du F; Jia W; Xu F; Wang F; Yang J; Niu W; Li C
Br J Pharmacol; 2015 Feb; 172(4):1059-73. PubMed ID: 25297453
[TBL] [Abstract][Full Text] [Related]
17. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
18. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
19. Use of gadoxetate disodium for functional MRI based on its unique molecular mechanism.
Choi Y; Huh J; Woo DC; Kim KW
Br J Radiol; 2016; 89(1058):20150666. PubMed ID: 26693795
[TBL] [Abstract][Full Text] [Related]
20. Unusual Distribution Kinetics of Gadoxetate in Healthy Human Subjects Genotyped for OATP1B1: Application of Population Analysis and a Minimal Physiological-Based Pharmacokinetic Model.
Weiss M; Siegmund W
J Clin Pharmacol; 2021 Apr; 61(4):506-514. PubMed ID: 33084108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
